[Serum levels of levonorgestrel during long-term use of Norplant]
- PMID: 11360617
[Serum levels of levonorgestrel during long-term use of Norplant]
Abstract
Objective: (1) Assessment of longest effective contraceptive duration of Norplant (containing levonorgestrel, LNG) by serum levonorgestrel levels. (2) To observe the possible relationships between the serum LNG levels of long-term use (5 years) and body weight.
Methods: To determine serum LNG levels in 230 women among 1,356 cases at various intervals between 1 and 11 years after implantation using RIA kits provided by WHO.
Results: The average serum levels of LNG in users of Norplant at the 1st, 3rd, 5th years were 1,273.5, 924.0 and 739.6 pmol/L respectively. From the 5th to 7th years average serum LNG levels showed almost a linear decline, and from the 7th through 10th year it did not show much changes. The average serum LNG level was (511.1 +/- 209) pmol/L. A significant negative correlation was found between serum LNG levels and body weight at the 5th years.
Conclusion: One set of Norplant implants may provide effective contraception for 8-10 years in women with body weights less than 60 kg.
Similar articles
-
Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system.Contraception. 2009 Jul;80(1):84-9. doi: 10.1016/j.contraception.2009.01.004. Epub 2009 Feb 27. Contraception. 2009. PMID: 19501221
-
First week drug concentrations in women with levonorgestrel rod or Norplant capsule implants.Contraception. 1997 Nov;56(5):317-21. doi: 10.1016/s0010-7824(97)00153-4. Contraception. 1997. PMID: 9437561 Clinical Trial.
-
Sex hormone binding globulin and free levonorgestrel index in the first week after insertion of Norplant implants.Contraception. 1998 Oct;58(4):211-4. doi: 10.1016/s0010-7824(98)00102-4. Contraception. 1998. PMID: 9866001
-
Mirena (Levonorgestrel intrauterine system): a successful novel drug delivery option in contraception.Adv Drug Deliv Rev. 2009 Aug 10;61(10):808-12. doi: 10.1016/j.addr.2009.04.022. Epub 2009 May 13. Adv Drug Deliv Rev. 2009. PMID: 19445984 Review.
-
The levonorgestrel intrauterine system in nulliparous women.Contraception. 2007 Jun;75(6 Suppl):S12-5. doi: 10.1016/j.contraception.2007.01.018. Epub 2007 Apr 3. Contraception. 2007. PMID: 17531602 Review.
Cited by
-
Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery.Cochrane Database Syst Rev. 2021 Dec 20;12(12):CD005072. doi: 10.1002/14651858.CD005072.pub4. Cochrane Database Syst Rev. 2021. PMID: 34928503 Free PMC article.
-
Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants.Drug Saf. 2003;26(5):303-35. doi: 10.2165/00002018-200326050-00002. Drug Saf. 2003. PMID: 12650633 Review.
-
Hormonal treatment for severe hydronephrosis caused by bladder endometriosis.Case Rep Urol. 2014;2014:891295. doi: 10.1155/2014/891295. Epub 2014 Nov 18. Case Rep Urol. 2014. PMID: 25506035 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources